menu
    • menu

    Company profile for CSL Behring

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. ...
    CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CSL BehringUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    HQ; 1020 First AvenueA
    Telephone
    Telephone
    +1 610-878-4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cslbehring.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CSL Earmarks $1.5B For US Production Expansion Over Next 5 Years
    CSL Earmarks $1.5B For US Production Expansion Over Next 5 Years

    18 Nov 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/australias-csl-plans-invest-15-billion-us-plasma-therapy-expansion-2025-11-18/

    REUTERS
    18 Nov 2025
    Share Share
    CSL Delays Spin-Off, Lowers Profit Outlook Amid Declining US
    CSL Delays Spin-Off, Lowers Profit Outlook Amid Declining US

    27 Oct 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/australias-csl-delays-vaccine-division-spin-off-amid-us-market-volatility-2025-10-27/

    REUTERS
    27 Oct 2025
    Share Share
    ISPE Names CSL Behring Winner Of 2025 Facility Of The Year Award
    ISPE Names CSL Behring Winner Of 2025 Facility Of The Year Award

    27 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ispe-names-csl-behring-the-2025-ispe-facility-of-the-year-awards-foya-overall-winner-for-its-project-aurora-plasma-base-fractionation-facility-facility-f-302595608.html

    PR NEWSWIRE
    27 Oct 2025
    Share Share
    Sanofi's $1.7B Bet Beats Csl's Zemaira In Phase 2 Face-Off
    Sanofi's $1.7B Bet Beats Csl's Zemaira In Phase 2 Face-Off

    22 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sanofis-17b-rare-disease-bet-beats-csls-zemaira-phase-2-face

    FIERCE BIOTECH
    22 Oct 2025
    Share Share
    CSL Behring, pCPA Sign LOI For HEMGENIX Gene Therapy In Hem B
    CSL Behring, pCPA Sign LOI For HEMGENIX Gene Therapy In Hem B

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/csl-behring-signs-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-pcpa-for-public-reimbursement-of-hemgenix-etranacogene-dezaparvovec

    PHARMIWEB
    07 Oct 2025
    Share Share
    CSL Behring Receives FDA Warning Letter
    CSL Behring Receives FDA Warning Letter

    16 Sep 2025

    // FDA

    https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/csl-behring-716297-09092025

    FDA
    16 Sep 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

    Details:

    Anumigilimab is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Anemia, Sickle Cell.


    Lead Product(s): Anumigilimab,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 04, 2025

    blank

    01

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Anumigilimab,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

    Details : Anumigilimab is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Anemia, Sickle Cell.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    4F-PCC Safety & Efficacy In Adults Undergoing Complex Cardiovascular Surgery with CPB

    Details:

    BE1116 is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of unspecified medical condition.


    Lead Product(s): BE1116,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 30, 2025

    blank

    02

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BE1116,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    4F-PCC Safety & Efficacy In Adults Undergoing Complex Cardiovascular Surgery with CPB

    Details : BE1116 is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of unspecified medical condition.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    July 30, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CSL222 Single-Dose Safety In Adolescent Males with Hemophilia B

    Details:

    Etranacogene Dezaparvovec is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hemophilia B.


    Lead Product(s): Etranacogene Dezaparvovec,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Cell & Gene Therapy

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 23, 2025

    blank

    03

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Etranacogene Dezaparvovec,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CSL222 Single-Dose Safety In Adolescent Males with Hemophilia B

    Details : Etranacogene Dezaparvovec is a Cell and Gene Therapy drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Hemophilia B.

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : Inapplicable

    July 23, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    IgPro20 SC PK, Safety & Tolerability In IG-Naïve PID Patients

    Details:

    IgPro is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Immunologic Deficiency Syndromes.


    Lead Product(s): IgPro,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 22, 2025

    blank

    04

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IgPro,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    IgPro20 SC PK, Safety & Tolerability In IG-Naïve PID Patients

    Details : IgPro is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Immunologic Deficiency Syndromes.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    July 22, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Dose-Finding and Safety of CSL787 In Non-CF Bronchiectasis

    Details:

    CSL787 is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Bronchiectasis.


    Lead Product(s): CSL787,Inapplicable

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Protein

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 02, 2025

    blank

    05

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CSL787,Inapplicable

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dose-Finding and Safety of CSL787 In Non-CF Bronchiectasis

    Details : CSL787 is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Bronchiectasis.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Inapplicable

    July 02, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Effect of Food on Oral Bioavailability of Prolonged-Release Vamifeport in Healthy Adults

    Details:

    Vamifeport is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


    Lead Product(s): Vamifeport,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 30, 2025

    blank

    06

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vamifeport,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effect of Food on Oral Bioavailability of Prolonged-Release Vamifeport in Healthy Adults

    Details : Vamifeport is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 30, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

    Details:

    Garadacimab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angioedemas, Hereditary.


    Lead Product(s): Garadacimab,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 04, 2025

    blank

    07

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Garadacimab,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacim...

    Details : Garadacimab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angioedemas, Hereditary.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    February 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    First Patients Receive Hemgenix Gene Therapy for Hemophilia B in Denmark

    Details:

    Hemgenix (etranacogene dezaparvovec-drlb) is an AAV5 based gene therapy designed to deliver a copy of a gene encoding hFIX-Padua in patients with Hemophilia B.


    Lead Product(s): Etranacogene Dezaparvovec,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Hemgenix

    Study Phase: Approved FDFProduct Type: Cell & Gene Therapy

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 21, 2025

    blank

    08

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Etranacogene Dezaparvovec,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First Patients Receive Hemgenix Gene Therapy for Hemophilia B in Denmark

    Details : Hemgenix (etranacogene dezaparvovec-drlb) is an AAV5 based gene therapy designed to deliver a copy of a gene encoding hFIX-Padua in patients with Hemophilia B.

    Product Name : Hemgenix

    Product Type : Cell & Gene Therapy

    Upfront Cash : Inapplicable

    January 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

    Details:

    Lonoctocog Alfa is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.


    Lead Product(s): Lonoctocog Alfa,Inapplicable

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 17, 2024

    blank

    09

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lonoctocog Alfa,Inapplicable

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A...

    Details : Lonoctocog Alfa is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    December 17, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults

    Details:

    Vamifeport is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Vamifeport,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 10, 2024

    blank

    10

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed

    CSL Behring

    U.S.A
    arrow
    Global ChemShow
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vamifeport,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healt...

    Details : Vamifeport is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    December 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact CSL Behring and get a quotation

    CSL Behring is a supplier offers 2 products (APIs, Excipients or Intermediates).

    Find a price of Water bulk with CEP offered by CSL Behring

    Find a price of ISCOMATRIX ADJUVANT bulk offered by CSL Behring

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search